Filing Details
- Accession Number:
- 0000950170-24-136025
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-12-12 20:44:00
- Reporting Period:
- 2024-12-10
- Accepted Time:
- 2024-12-12 20:44:00
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1744659 | Akero Therapeutics Inc. | AKRO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1779479 | Timothy Rolph | 601 Gateway Boulevard Suite 350 South San Francisco CA 94080 | Chief Scientific Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2024-12-10 | 2,368 | $30.79 | 178,337 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-12-10 | 2,450 | $19.87 | 180,787 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-12-10 | 2,450 | $31.03 | 178,337 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-12-10 | 2,450 | $0.00 | 2,450 | $19.87 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 138,755 | 2033-12-08 | No | 4 | M | Direct |
Footnotes
- Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.79 to $30.99, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 12, 2024, previously adopted by the Reporting Person.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.13, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing from December 8, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Billionaire Hedge Funds
